Insulin supply at risk as drugmakers focus on GLP-1s, says report

The 2026 Access to Medicine Index says GLP-1 drugs make up most of the diabetes pipeline, while only 10 of 25 projects target type 1 diabetes. Some insulin makers are cutting older products, it added. The Access to Medicine Foundation's CEO Jay Iyer told The Guardian that Sanofi, Eli Lilly or Novo Nordisk could leave the insulin market.